Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“TALAPRO-3 ASCO26
Talazoparib + enzalutamide in HRR-altered mCSPC prostate looks the most impressive PARPi data to date.
Efficacy in the non-BRCA HRR population is impressive IMO. Long term treatment is associated with long term side effects.”
Other articles featuring Tom Powles on OncoDaily.
